Century Therapeutics (IPSC) News Today

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,790,000 shares, a growth of 14.7% from the June 15th total of 1,560,000 shares. Based on an average daily volume of 202,000 shares, the days-to-cover ratio is currently 8.9 days. Approximately 5.2% of the company's shares are sold short.

Century Therapeutics (NASDAQ:IPSC) Trading Down 7.7%

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Gregory Russotti sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $2.84, for a total value of $14,200.00. Following the sale, the insider now directly owns 277,319 shares of the company's stock, valued at $787,585.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Piper Sandler lifted their target price on shares of Century Therapeutics from $9.00 to $12.00 and gave the stock an "overweight" rating in a research report on Monday.

Avidity Partners Management LP increased its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 23.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,355,000 shares of th

HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Century Therapeutics in a research note on Tuesday.

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,560,000 shares, a drop of 9.8% from the April 15th total of 1,730,000 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 194,700 shares, the short-interest ratio is currently 8.0 days.

HC Wainwright dropped their target price on shares of Century Therapeutics from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Friday.

Piper Sandler reiterated an "overweight" rating and issued a $9.00 target price (down previously from $10.00) on shares of Century Therapeutics in a report on Friday.

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,640,000 shares, a decline of 6.3% from the February 29th total of 1,750,000 shares. Based on an average daily trading volume, of 214,300 shares, the short-interest ratio is presently 7.7 days. Approximately 7.6% of the company's shares are sold short.

Canaccord Genuity Group lifted their price objective on Century Therapeutics from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday.

HC Wainwright restated a "buy" rating and set a $13.00 price target on shares of Century Therapeutics in a report on Friday.

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have give

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Adrienne Farid sold 22,831 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $5.14, for a total transaction of $117,351.34. Following the transaction, the insider now directly owns 114,149 shares in the company, valued at approximately $586,725.86. The transaction was disclosed in a filing with the SEC, which is available through this link.

Fmr LLC trimmed its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 12.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,524,629 shares of the company's stock after selling 643,

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 846,300 shares, a growth of 6.4% from the January 15th total of 795,600 shares. Currently, 3.7% of the company's shares are sold short. Based on an average daily volume of 183,100 shares, the days-to-cover ratio is currently 4.6 days.